Intervention Group:CAR-T cell

2 trials

Sponsors

The Second Hospital of Hebei Medical University, Hebei Yanda Ludaopei Hospital

Conditions

B-cell hematologic malignancieshematopoietic and lymphoid malignancies

Unknown Phase

A clinical study of chimeric-antigen-receptor-tranduced T cells in the treatment of B-cell hematologic malignancies

RecruitingChiCTR-ONC-17011211

The Second Hospital of Hebei Medical UniversityB-cell hematologic malignancies

Start: 2016-05-01Updated: 2017-04-24

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

RecruitingChiCTR-ONC-17012829

Hebei Yanda Ludaopei Hospitalhematopoietic and lymphoid malignancies

Start: 2017-08-29Updated: 2017-10-02

Related Papers

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Blood2022-11-151 citations

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.

2021-08-0736 citations

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2020-11-044 citations

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Blood2020-11-043 citations

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood2019-11-134 citations